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Abstract: The amygdala is a cerebral region whose function is compromised in temporal lobe epilepsy
(TLE). Patients with TLE present cognitive and emotional dysfunctions, of which impairments in
recognizing facial expressions have been clearly attributed to amygdala damage. However, damage to
the amygdala has been scarcely addressed, with the majority of studies focusing on the hippocampus.
The aim of this study was to evaluate epilepsy-related plasticity of cholinergic projections to the
basolateral nucleus (BL) of the amygdala. Adult rats received kainic acid (KA) injections and
developed status epilepticus. Weeks later, they showed spontaneous recurrent seizures documented
by behavioral observations. Changes in cholinergic innervation of the BL were investigated by using
an antibody against the vesicular acetylcholine transporter (VAChT). In KA-treated rats, it was found
that (i) the BL shrunk to 25% of its original size (p < 0.01 vs. controls, Student’s t-test), (ii) the density of
vesicular acetylcholine transporter-immunoreactive (VAChT-IR) varicosities was unchanged, (iii) the
volumes of VAChT-IR cell bodies projecting to the BL from the horizontal limb of the diagonal band
of Broca, ventral pallidum, and subcommissural part of the substantia innominata were significantly
increased (p < 0.05, Bonferroni correction). These results illustrate significant changes in the basal
forebrain cholinergic cells projecting to the BL in the presence of spontaneous recurrent seizures.
Keywords: acetylcholine; basolateral nucleus of amygdala; basal forebrain; kainic acid; neuronal
plasticity; temporal lobe epilepsy
1. Introduction
Epilepsy is a neurological disease [1] affecting 65 million people around the world [2].
Associated with inherent comorbidities, this condition brings about decreased life expectancy, impaired
life quality, loss of working years, and heavy healthcare costs [3–7]. The enduring tendency of
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generating spontaneous recurrent seizures, which characterizes epilepsy, is believed to be due to
neuroplastic alterations at molecular, cellular, and circuitry levels, such as aberrant neurogenesis
subsequent to the death of susceptible cell populations, rewiring, neuronal hyperexcitability and/or
hypoexcitability, and other pathophysiological changes, including neuroinflammation and alterations
in the extracellular matrix and blood–brain barrier [8–12]. Temporal lobe epilepsy (TLE) accounts for
approximately 75% of epilepsy cases in adults, and is the most prevalent type of focal epilepsy in that
population [13–15].
The administration of kainic acid (KA) to rodents [16–20] followed by status epilepticus (SE)
represents one of the best characterized models of TLE, which, compared to other animal models, most
closely mimics the behavioral, histopathologic, electrographic, and drug-response features of human
TLE [21–27]. Previous works from our group have found that the KA model of TLE is characterized by
neuroplastic alterations in cholinergic neurons of the medial septum and vertical limb of the diagonal
band of Broca (MS/VDB) projecting to the hippocampal formation [28], as well as in the brainstem
pedunculopontine and laterodorsal nuclei [29]. Since the amygdaloid complex, or more precisely its
basolateral (basal) nucleus (BL), receives the densest cholinergic terminal projection in the central
nervous system of both rodents and primates [30–32], and because various subdivisions of the BL
undergo remarkable structural changes in epilepsy, we found it of interest to evaluate the effects of
KA-induced epilepsy on the BL cholinergic afferents.
2. Results
2.1. Monitoring for Spontaneous Seizures
Two rats died acutely within 24 h following treatment with KA. During the first four weeks
following KA injection, spontaneously recurrent stage 1–3 seizures on the Racine scale [21,33], that is,
uncontrolled mouth and facial clonic movements and moderate forelimb clonus, were observed in only
three rats from the KA group. However, in the remaining period of observation, all rats in the KA group
displayed spontaneous stage 1–3 seizures. At least two spontaneous generalized behavioral seizures
of stage 4–5 on the Racine scale were documented in all remaining KA-treated rats. Thus, the final
group size for the KA-treated rats was n = 6. No behavioral seizures were observed in the control
group (n = 6).
2.2. Basolateral Nucleus Volume
Figure 1 shows representative images of level-matched sections cut through the BL and stained
for vesicular acetylcholine transporter (VAChT) of a control rat and a KA-treated epileptic rat. As can
be seen in these images, the epileptic state was associated with a decrease in volume of the BL.
Volumes of the BL, estimated with an average coefficient of errors equal to 0.019, are shown in Figure 2
for both groups. Statistical comparisons of these estimates confirm significant shrinkage of the BL,
approximately 25%, in KA rats, when compared to control rats (p < 0.01, Student’s t-test).
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Figure 1. (a) Photograph of a representative Nissl-stained coronal section cut through the anterior part
of the temporal lobe and showing the location of the basolateral nucleus (BL) relative to the neighboring
lateral (Lat) and intercalated (I) nuclei. Scale bar, 200 µm. (b,c) Photomicrographs of representative
vesicular acetylcholine transporter (VAChT)-stained sections obtained from control and post-SE rats,
respectively. Note that the BL is more densely stained when compared to the lateral nucleus and other
surrounding amygdaloid nuclei. The images are suggestive of moderate shrinkage of the BL in the
post-SE rat. Scale bar, 200 µm. (d,e) Higher-power photomicrographs taken from the areas shown in
insets (b,c), respectively. Note that the density of VAChT-stained fibers and fiber varicosities do not
differ between the rats. Scale bar, 30 µm.
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Figure 2. Effect of KA-induced status epilepticus (SE) on the total volume of the BL (mean ± standard
deviation). Note that kainate treatment resulted in a 25% shrinkage of the BL as delineated in
immunostained material (Figure 1). * p < 0.01, Student’s t-test.
2.3. Density of VAChT-Immunoreactive Fiber Varicosities
Representative photomicrographs shown in Figure 1b–e illustrate VAChT-immunoreactive fibers
organized in a dense network of terminals, which bear many varicosities of different shapes and sizes
in the rat BL. However, the densities of the fibers and varicosities do not appear to differ considerably
between control rats and post-SE rats. Figure 3 shows quantitative estimates of the areal density of
VAChT-IR varicosities in the BL of control rats and post-SE rats. Both visual inspection of this plot and
statistical analysis of the estimates (Student’s t-test) confirmed no differences between the two groups
(p > 0.05).
Figure 3. Graphic representation of the quantitative estimates obtained for the areal densities of
vesicular acetylcholine transporter (VAChT)-stained varicosities in the BL of control and epileptic
rats (see Figure 1). Values represent mean ± standard deviation. No differences between the groups
were found.
2.4. Somatic Volume of VAChT-Immunoreactive Cells
Figure 4 shows representative microphotographs of VAChT-immunostained sections cut through
the basal forebrain of a control rat (a,b) and a KA-treated epileptic rat (g,h). As can be inferred from the
higher-power images in Figure 4c–f,i–l, respectively, the VAChT-IR cells of epileptic rats possess larger
perikarya compared to respective cells of control rats. The mean somatic volumes of the VAChT-stained
cells measured in four distinct areas of the basal forebrain are graphically represented in Figure 5.
Multivariate analysis of variance (MANOVA) of these data yielded a significant main effect of treatment
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(Rao’s R4,5 = 6.65, p < 0.05). Bonferroni correction for multiple comparisons revealed that the perikarya
of cholinergic cells were significantly enlarged in post-SE rats in the horizontal limb of the diagonal
band of Broca (HDB; 44%, p < 0.05), ventral pallidum (VP; 75%, p < 0.005), and substantia innominata
(SI; 66%, p < 0.005), but not in the magnocellular preoptic nucleus (MCPO; 9%, p > 0.05).
Figure 4. (a,b) Photomicrographs of representative vesicular acetylcholine transporter (VAChT)-stained
coronal sections obtained from the brain of a control rat and showing four subdivisions of the basal
forebrain projecting to the BL, horizontal limb of the diagonal band of Broca (HDB) (c), subcommissural
part of substantia innominata (SI) (d), magnocellular preoptic nucleus (MCPO) (e), and ventral pallidum
(VP) (f). The sections shown in (a,b) were cut approximately at levels of –0.72 and –1.20 mm, posterior
to bregma, respectively (c–f). Higher-power photomicrographs of neurons indicated in (a,b) by arrows
and belonging to the four basal forebrain subdivisions. (g,h) Photomicrographs of the respective
VAChT-stained sections obtained from an epileptic rat. The sections (a–g,b–h) were cut at approximately
the same levels relative to the bregma. (i–l) Higher-power photomicrographs of neurons found in the
HDB, SI, MCPO, and VP of the epileptic rat. Precise locations of these neurons in the basal forebrain
subdivisions are shown by arrows in (g,h). Note that neurons located in the HDB, SI, and VP of the
epileptic rat possess larger perikarya than respective neurons of the control rat. Scale bars, 400 (a,b,g,h)
and 30 µm (c–f,i–l).
Int. J. Mol. Sci. 2019, 20, 5688 6 of 14
Figure 5. Graphic representation of stereological estimates for the mean somatic volume (mean ±
standard deviation) of vesicular acetylcholine transporter-immunoreactive (VAChT-IR) cells in four
distinct subdivisions of the basal forebrain (Figure 4). Note that post-SE rats have enlarged cholinergic
neurons located in the horizontal limb of the diagonal band of Broca (HBD), ventral pallidum (VP),
and substantia innominata (SI), but not in magnocellular preoptic nucleus (MCPO). * p < 0.05 and ** p <
0.005 vs the respective control region, Bonferroni correction.
3. Discussion
The basolateral region of the amygdala is densely innervated by cholinergic afferents originating
in different subdivisions of the basal forebrain, which suggests an important role of acetylcholine in
modulating amygdala functions, including the processing of memory and emotion [34–36]. The main
results of the present study are that, in epilepsy, this projection system undergoes severe modifications,
which include significant decreases of that part of the amygdala that receives the densest cholinergic
innervation, and abnormal increases of the perikarya of cells projecting to that part. Thus, it is likely
that the changes in the amygdalopetal cholinergic connections to the basal forebrain described here
may contribute to epilepsy-related hyperexcitability of amygdaloid neurons and comorbid deficits in
amygdala-dependent behaviors.
Compared to the large body of data regarding the hippocampal pathology in TLE and respective
animal models, the pathology of the amygdala in epilepsy has been relatively overlooked, having
been addressed in just a few studies [37–44]. However, the amygdala is equally acknowledged as a
brain area of very low ictal threshold, and kindling of the amygdala is one of the best known and
characterized models of epilepsy [45,46]. Furthermore, in models where focal seizures are elicited
in extra-amygdaloid areas, the amygdala plays a pivotal role in seizure spreading. For instance,
in the audiogenic model of seizures, the ictal activity initiated in a primary brainstem focus (inferior
colliculus of the mesencephalon) subsequently recruits the amygdala via the medial geniculate body
prior to spreading to other forebrain structures [47–49]. Moreover, in human TLE, the amygdala
can contain the main epilepsy focus in 5% of patients [50]. In the present study, we found that
chronic epilepsy in rats is associated with dramatic shrinkage of the BL, which is consistent with the
results of prior studies [41,51–56]. Similarly, magnetic resonance volumetric measurements of the
amygdala in TLE have shown an average 20% volume reduction in 19% of the general population
with TLE [57,58], and a 10%–30% volume reduction in patients with drug-refractory TLE [52,54].
Shrinkage of the amygdala in epilepsy is likely to result from neurodegenerative changes in this brain
region, similar to those described in hippocampal sclerosis. Indeed, significant neuronal loss or reactive
gliosis were reported in the basal [41,59] and lateral [41,60,61] nuclei of the amygdala in TLE patients.
In animal models, some amygdala components, including the anterior cortical and medial nuclei,
the medial division of the lateral nucleus, the parvicellular division of the basal nucleus, and the
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accessory basal nucleus were reported to be more susceptible to neuron loss with respect to other
cerebral regions [37,39,41]. In addition, there is evidence that GABAergic interneurons are particularly
vulnerable to seizure-induced damage [37–41,62], which leads to impaired feed-forward inhibition of
principal amygdaloid neurons [63].
Cholinergic afferents play an important role in modulating the excitability of intrinsic neuronal
circuits of the amygdala. The vast majority of cholinergic terminals form symmetric (putatively
inhibitory) synapses on the dendritic shafts and spines of principal pyramidal neurons and on the
perikarya of interneurons [64,65]. However, parts of the synapses possess characteristics of excitatory
synapses [65] and principal cells of the amygdala are rich in both M1 (depolarizing) [66] and M2
(hyperpolarizing) [67] muscarinic receptors. Thus, it is plausible that cholinergic afferents have rather
modulatory than inhibitory effects in the amygdala. Complementing previous experiments that
illustrated an approximate 20% reduction in choline acetyltransferase activity [68], accompanied by a
remarkable decrease in muscarinic receptor binding, we found that the areal density of cholinergic
terminals was unchanged in the epileptic BL despite the considerable reduction of the total BL volume
innervated by cholinergic fibers. Considered together with prior data showing preferential loss of
GABAergic neurons in the amygdala of epileptic animals [37–39,62], our results suggest that induction
of the chronic epilepsy state, at least in this model, alters the main pattern of cholinergic innervation
in the BL. More specifically, it can be hypothesized that the cholinergic terminals, due to GABAergic
cell loss, were relocated toward new targets, which could be dendritic and somatic membranes of
pyramidal cells. This mechanism may be either compensatory, that is, aimed to provide additional
inhibitory drive upon hyperexcitable BL principal neurons, or, in contrast, it may contribute to their
hyperexcitability. Although further studies are necessary to address this issue in detail, the present
findings clearly show that reorganization of the BL cholinergic network is likely to be one of the
fundamental mechanisms underlying amygdala dysfunction in epilepsy.
These findings are consistent with our previous reports showing that KA-induced SE triggers
marked reorganization of cholinergic afferents in the hippocampal formation, namely relocation
of VAChT-containing terminals from the hilus of the dentate gyrus to its molecular layer [28,69].
This reorganization was found to be associated with a general activation of the septohippocampal
cholinergic projection system, as indicated by the fact that cholinergic cells located in the MS/VDB
regions projecting to the dentate gyrus of epileptic rats had approximately 40% larger cell bodies
compared to control rats [28]. In this study, we estimated the somatic volumes of cholinergic cells in
four distinct subdivisions of the basal forebrain, all of which project to the BL, although to different
extents. In the HDB the cholinergic cells were enlarged by 44%, which is similar to what was previously
found in the MS/VDB. Yet, even more profound hypertrophic changes were found in VAChT-IR cells
located in the VP (75%) and SI (66%), suggesting that these regions are particularly implicated in
epilepsy-related cholinergic plasticity. These data are compatible with the results of neuroanatomical
studies showing that VP and SI neurons make a major contribution to cholinergic innervation of the
amygdala [31,70,71]. Interestingly, neurons located in the MCPO, which send only a small number
of cholinergic afferents to the amygdala, were not significantly enlarged. Although the importance
of cholinergic plasticity in epilepsy is not yet clarified, the results of one study [72] indicate that
site-specific inhibition of neuronal hypertrophy in the medial septum reduces seizure susceptibility
and partially prevents epileptogenesis in a subset of KA-treated rats. Considered together with the
present findings, these data suggest that a more widespread blockage of seizure-driven cholinergic
hypertrophy, including in the medial septum and the regions examined in this study, might provide
better protection against seizures and epileptogenesis.
In conclusion, the present study provides the first evidence of hypertrophic changes in the
basal forebrain cholinergic cells projecting to the amygdala. These findings support the idea that
epilepsy-related neuroplasticity of the forebrain cholinergic neurons can contribute to epileptogenesis
as well as to epilepsy-related comorbid diseases. Thus, unraveling the biochemical pathways and
physiological mechanisms that prompt hypertrophic changes in cholinergic neurons may offer new
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molecular targets for the development of novel therapeutic approaches to drug-resistant types
of epilepsy.
4. Materials and Methods
4.1. Ethical Statement
The handling and care of animals was conducted according to the “Principles of laboratory animal
care” (NIH publication No. 86–23, revised in 1985) [73] and Directive 2010/63/EU of the European
Parliament. All experiments have been previously carefully evaluated and received approval by the
Ethics Committee (Faculty of Medicine of Porto) and the General Veterinary Direction (3 April 2012)
for the FCT application grant PTDC/SAU-NSC/115506/2009. Animals used were only those strictly
required for the experiments and suffering was limited as much as possible.
4.2. Animals and Treatments
Ten-week-old male Wistar rats were randomly assigned to two groups, respectively, and given
intraperitoneal (i.p.) injections of either kainic acid, 9.5 mg/kg, (KA group, n = 9) or the corresponding
volume of saline (Ctrl group, n = 6). The animals were placed in individual boxes for behavioral
observation and quantification for 6 h. Motor seizures were scored according to the modified Racine
scale for generalized motor seizures of focal limbic initiation [21,33]. The onset of SE was defined as
seizures scored as Racine’s stage 3–5, lasting for at least 20 min with no recovery of “baseline” behavior,
such as grooming, sniffing, and exploratory activity [74]. One animal from the KA group exhibited
numerous wet dog shake seizures, but did not reach Racine’s stage 3 or higher; this rat was excluded
from the experiment. No seizure-like behavior was observed in rats given saline. Post-SE care consisted
of evaluating the general state of animals twice a day, and giving subcutaneous saline injections,
as well as moisturized chow from a plastic syringe. Starting from the second week after KA or vehicle
treatments, the rats were daily monitored (except weekends) for the appearance of spontaneous motor
seizures during at least two 2 h intervals (9:00–11:00 and 14:00–16:00) by an investigator blind to
treatment groups.
4.3. Immunohistochemistry and Histology
Four months after the induction of SE, i.p. pentobarbital (90 mg/kg) was administered to animals
to induce a deep anesthesia; then, animals were transcardially perfused with phosphate buffered
saline (PBS), pH 7.4, 150 mL for vascular rinse, followed by paraformaldehyde 4% diluted in PBS,
250 mL for fixation. After removal, brains were immersed in fixative for 2 h and then immersed in 10%
sucrose solution for 36 h at 4 ◦C. Afterwards, brains were vibratome-cut in 40 µm sections and stored
in cryoprotectant (sucrose 30%, ethylene glycol 30%, polyvinylpirrolidone 0.25%, in PBS) at –20 ◦C
until use.
Every sixth section, including basal forebrain and BL, was systematically sampled and
immunostained for VAChT. Preceding primary antibodies, sections were rinsed in PBS (3 times)
and endogenous peroxidases were blocked by immersing the sections in 1% H2O2 PBS solution for
15 min. Then, sections were washed in PBS (6 times, 5 min each) and blocked for nonspecific staining
by immersion in 10% normal goat serum (NGS) + 0.5% Triton X-100 in PBS. Subsequently, sections
were incubated in the presence of a VAChT guinea-pig primary antibody (Merck Millipore AB1588;
1:1250 dilution in PBS) for 72 h at 4 ◦C. After washing in PBS containing 2% NGS (3 times, 10 min each),
sections were incubated with a biotinylated anti-guinea-pig antibody (BA7000, Vector Laboratories,
Burlingame, CA 94010, USA, diluted 1:200 in 0.02 M PBS). Finally, sections were washed 3 times (10 min
each) and incubated with avidin-biotin-peroxidase complex (Vector laboratories, Vectastain Elite ABC
Kit) to perform the peroxidase reaction with 3,3’-diaminobenzidine (1 mg/mL) and H2O2 (0.08% in
PBS). Further washing (2 times) with PBS preceded section mounting on gelatin-coated slides and
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overnight drying. For glass coverslipping, sections were dehydrated and covered with Histomount
(National Diagnosis, Atlanta, GA, USA).
Nissl staining was performed using another set of regularly sampled sections (1:6), which were
mounted on gelatin-coated slides and air-dried to be stained with Giemsa, dehydrated, and coverslipped
with Histomount.
4.4. Density of VAChT-Immunoreactive Varicosities
Three to four consecutive VAChT-stained sections containing the BL were sampled from each
brain. Sections were level-matched in all animals included in our analysis, by means of the rat brain
atlas [75]. An Axio Scope.A1 microscope (Zeiss, Germany) equipped with a Leica EC3 color digital
camera was used to visualize sections. BL boundaries were defined with a 10× objective lens on the
basis of the rat brain atlas. For the purposes of the present study, we did not distinguish between the
subdivisions of the BL nucleus [35,75]. In each section, four photomicrographs of the central area of
the BL were taken, bilaterally, with a 100× objective lens, totaling 24–32 images per animal. Using the
Fiji image-processing software (http://rsb.info.nih.gov/ij/) and a frame of 1421 µm2 superimposed onto
each image, we measured all varicosities and their respective cross-sectional areas as found within the
frame. Only fiber varicosities within cross-sectional areas ranging between 0.11 and 0.21 µm2 were
then included for further analysis. Varicosities’ densities were normalized using an arbitrary area of
30,000 µm2 and averaged for all sections/animal.
4.5. Estimation of BL Volume
An Olympus BX-53 microscope equipped with a computer-controlled motorized stage system (MBF
Bioscience, Williston, ND, USA) was used to visualize all sections containing the BL. The boundaries
of the BL were consistently defined at all levels along the rostrocaudal axis using the rat brain atlas
and the distinct pattern of BL VAChT staining, which is characteristic of this part of the amygdaloid
complex. Estimations were carried out using the Cavalieri estimator probe of the Stereo Investigator
software (MBF Bioscience). The regions of interest were delineated with a 4× objective lens and a grid
size of 20 × 20 µm2 was applied.
4.6. Estimation of Somatic Volume of VAChT-Immunoreactive Neurons
VAChT-stained cells were sampled using an optical fractionator probe (Stereo Investigator
software, MBF Bioscience, Williston, VT 05495, USA) to measure each somatic volume. The nucleator
probe for isotropic systematically random sampled sections was used for measurements [76], and each
cellular nucleolus was set as a central point. The estimates included the HDB, MCPO, VP, and the
subcommissural part of SI. The ROIs were carefully outlined using a 10× objective lens, according
to [75] for the HDB and MCPO, and [77] for the VP and SI. The coefficient of error for each individual
estimate was inferior to 0.04 in all measurements for each animal.
4.7. Statistics
The volumes of cell bodies were analyzed using MANOVA followed by the Bonferroni post-hoc
test for multiple comparisons (Bonferroni correction). The estimates of the BL volume and the density
of VAChT-IR varicosities were analyzed by the two-tailed Student’s t-test. Results were presented as
mean ± SD.
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Abbreviations
TLE temporal lobe epilepsy
KA kainic acid
SE status epilepticus
LD linear dichroism
MS medial septum
VDB vertical limb of the diagonal band of Broca
BL basolateral amygdaloid nucleus
VAChT vesicular acetylcholine transporter
HDB horizontal limb of the diagonal band of Broca
VP ventral pallidum
SI substantia innominata
MCPO magnocellular preoptic nucleus
PBS phosphate buffered saline
NGS normal goat serum
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